This article was originally published in The Tan Sheet
Breathe Right line extension expected to debut in March 2002, and CNS will enter a new product category later next year, company says during July 19 analysts call on Q2 results. Overall first-half sales reached $42.6 mil. compared to $27.9 mil. a year ago, while Q2 sales grew 16.5% to $15.5 mil., slightly outpacing earlier projections (1"The Tan Sheet" July 2, p. 8). "Disappointing" Fiberchoice sales of $5 mil. in first half causing CNS to reduce second-half marketing expenditures by about $7 mil. compared to first six months, company says
You may also be interested in...
CNS recorded a $1.2 mil. charge against earnings in the second quarter as part of a restructuring plan aimed at strengthening its core Breathe Right nasal strip business and returning the firm to sustainable profitability.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning